Clinical Professor Russell S. Scott, Our people, University of Otago, Christchurch

BMedSc MB ChB(Otago) PhD(Monash) FRACP

Department of Internal Medicine
Christchurch Hospital
Private Bag 4710
Christchurch
New Zealand

Email russell.scott@cdhb.govt.nz

Current Roles

Clinical Professor of Medicine, University of Otago, Christchurch, New Zealand
Consulting Physician: Diabetes, Endocrinology and Metabolism
Physician, Internal Medicine, Canterbury District Health Board
Consultant, NZ Clinical Research OpCo Ltd

Research Interests

Prevention and treatment of type 1 Diabetes Mellitus
Lipid disorders and cardiovascular disease
Complications and treatment of Type 2 diabetes
Novel metabolic treatment strategies
Gene editing and disease modification

Top 10 Publications

Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Scott R, Wasserman SM, Gaudet D; for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015: 385(9965), 331-40.
Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Causes of Death in a Contemporary Cohort of Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights from the TECOS Trial. Diabetes Care. 2017: 40(12), 1763-1770.
Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018: 20(12), 2876-2884.
Cao JY, Waldman B, O'Connell R, Sullivan DR, Scott RS, Aryal N, Gebski V, Marschner I, Taskinen MR, Simes JR, McGill N, Jenkins AJ, Keech AC; FIELD investigators. Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020: 22(8),1388-1396.
Page MM, Ekinci EI, Burnett JR, Hooper AJ, Reid N, Bishop W, Florkowski CM, Scott R, O'Brien RC, Watts GF. Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. J Clin Apher. 2021: 36(1), 48-58.
Ong KL, Wu L, Januszewski AS, O'Connell R, Xu A, Scott RS, Sullivan DR, Rye KA, Li H, Ma RC, Li L, Gebski V, Jenkins AJ, Jia W, Keech AC. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021: 18(4) 14791641211032547.
Willis J, Cunningham-Tisdall C, Griffin C, Scott R, Darlow BA, Owens N, Ferguson J, Mackenzie K, Williman J, de Bock M. Type 1 diabetes diagnosed before age 15 years in Canterbury, New Zealand: A 50 year record of increasing incidence. Pediatr Diabetes. 2021: 23(3), 301-309.

Quinn N, Januszewski AS, Brazionis L, O'Connell R, Aryal N, O'Day J, Scott R, Mitchell P, Jenkins AJ, Keech AC. Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy. FIELD Trial Study Group. Intern Med J. 2022: 52(4), 676-679.
Tetri Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander BA, Cusi K, Loomba R, Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol. 2023: 78(4), 684-692.
Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, Clifton P, Hamilton J, Given B, Melquist S, Zhou R, Chang T, San Martin J, Gaudet D, Goldberg IJ, Knowles JW, Hegele RA, Ballantyne CM. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts.. Nat Med. 2023: 29(9), 2216-2223.
Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D, Stein E; LIBerate-HeFH Investigators. Eur Heart J. 2023: 44(40), 4272-4280.

Publications

Willis, J., Cunningham-Tisdall, C., Griffin, C., Scott, R., Darlow, B. A., Owens, N., Ferguson, J., Mackenzie, K., Williman, J., & de Bock, M. (2022). Type 1 diabetes diagnosed before age 15 years in Canterbury, New Zealand: A fifty year record of increasing incidence. Pediatric Diabetes, 23, 301-309. doi: 10.1111/pedi.13305 Journal - Research Article

Scott, R. (2020, August). What's hot in diabetes? Plenary presentation at the South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand. Conference Contribution - Verbal presentation and other Conference outputs

Cao, J., Waldman, B., O'Connell, R., Sullivan, D., Gebski, V., Marschner, I., Scott, R., … on behalf of the FIELD Investigators. (2019). Baseline and short-term change in plasma uric acid on fenofibrate predict cardiovascular risk: A post hoc analysis of FIELD. Heart, Lung & Circulation, 28(Suppl. 4), (pp. S286-S287). doi: 10.1016/j.hlc.2019.06.354 Conference Contribution - Published proceedings: Abstract

Redondo, M. J., Geyer, S., Steck, A. K., Sharp, S., Wentworth, J. M., Weedon, M. N., … and Type 1 Diabetes TrialNet Study Group, including Scott, R., Heenan, H., Lunt, H., Willis, J., Darlow, B., Manning, P., Taylor, B., Jones, S., Wiltshire, E., & Krebs, J. (2018). A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care, 41(9), 1887-1894. doi: 10.2337/dc18-0087 Journal - Research Article

Scott, R., Morgan, J., Zimmer, Z., Lam, R. L. H., O'Neill, E. A., Kaufman, K. D., … Raji, A. (2018). A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes, Obesity & Metabolism, 20, 2876-2884. doi: 10.1111/dom.13473 Journal - Research Article

2022

Journal - Research Article

2020

Conference Contribution - Verbal presentation and other Conference outputs

Scott, R. (2020, August). What's hot in diabetes? Plenary presentation at the South General Practice Conference & Medical Exhibition (GP CME), Christchurch, New Zealand.

2019

Conference Contribution - Published proceedings: Abstract

2018

Journal - Research Article

2015

Journal - Research Article

Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civiera, F., Burgess, L., … Scott, R., … for the RUTHERFORD-2 Investigators. (2015). PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet, 385(9965), 331-340. doi: 10.1016/S0140-6736(14)61399-4

2012

Journal - Research Article

Young, J. M., Molyneux, S. L., Florkowski, C. M., Frampton, C. M., George, P. M., & Scott, R. S. (2012). Pharmacokinetic comparison of a generic coenzyme Q₁₀ solubilizate and a formulation with soybean phytosterols. Phytotherapy Research, 26, 1092-1096. doi: 10.1002/ptr.3667

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., & George, P. M. (2012). A randomized, double-blind, placebo-controlled crossover study of coenzyme Q₁₀ therapy in hypertensive patients with the metabolic syndrome. American Journal of Hypertension, 25(2), 261-270. doi: 10.1038/ajh.2011.209

2011

Journal - Research Article

Maclean, A., McKenney, J. M., Scott, R., Brinton, E., Bays, H. E., Mitchel, Y. B., … Maccubbin, D. L. (2011). Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. British Journal of Cardiology, 18(1), 37-45.

Callahan, A., Amarenco, P., Goldstein, L. B., Sillesen, H., Messig, M., Samsa, G. P., … Scott, R., … for the SPARCL Investigators. (2011). Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: Secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Archives of Neurology, 68(10), 1245-1251. doi: 10.1001/archneurol.2011.146

King, R. I., Florkowski, C. M., Yeo, J., Walmsley, T. A., Shand, B. I., Scott, R. S., & George, P. M. (2011). What is the best predictor of the atherogenic LDL subclass phenotype ‘pattern B’ in patients with type 2 diabetes mellitus? Annals of Clinical Biochemistry, 48(2), 166-169. doi: 10.1258/acb.2010.010185

Scott, R., Donoghoe, M., Watts, G. F., O'Brien, R., Pardy, C., Taskinen, M.-R., … Manning, P., … Keech, A. C. (2011). Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovascular Diabetology, 10, 102. doi: 10.1186/1475-2840-10-102

Meininger, G. E., Scott, R., Alba, M., Shentu, Y., Luo, E., Amin, H., … Goldstein, B. J. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care, 34(12), 2560-2566. doi: 10.2337/dc11-1200

Eady, S., Wallace, A., Willis, J., Scott, R., & Frampton, C. (2011). Consumption of a plant sterol-based spread derived from rice bran oil is effective at reducing plasma lipid levels in mildly hypercholesterolaemic individuals. British Journal of Nutrition, 105(12), 1808-1818. doi: 10.1017/S0007114510005519

Young, J. M., Molyneux, S. L., Reinheimer, A. M., Florkowski, C. M., Frampton, C. M., Scott, R., & George, P. M. (2011). Relationship between plasma coenzyme Q₁₀, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. Atherosclerosis, 218(1), 188-193. doi: 10.1016/j.atherosclerosis.2011.04.034

Sorrenson, B., Suetani, R. J., Bickley, V. M., George, P. M., Williams, M. J. A., Scott, R. S., & McCormick, S. P. A. (2011). An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations. Biochemical & Biophysical Research Communications, 409(3), 400-405. doi: 10.1016/j.bbrc.2011.05.006

Miller, L. J., Willis, J. A., Pearce, J., Barnett, R., Darlow, B. A., & Scott, R. S. (2011). Urban-rural variation in childhood type 1 diabetes incidence in Canterbury, New Zealand, 1980 to 2004. Health & Place, 17(1), 248-256. doi: 10.1016/j.healthplace.2010.10.010

2010

Journal - Research Article

Lever, M., George, P. M., Slow, S., Elmslie, J. L., Shand, B. I., Scott, R. S., & Chambers, S. T. (2010). Fibrates plus betaine: A winning combination? [Viewpoint]. New Zealand Medical Journal, 123(1324). Retrieved from http://journal.nzma.org.nz/journal/123-1324/4389/content.pdf

King, R. I., Scott, R. S., Florkowski, C. M., Laurie, A. D., Reid, N., & George, P. M. (2010). Homozygous familial hypercholesterolaemia and treatment by LDL apheresis [Clinical correspondence]. New Zealand Medical Journal, 123(1319). Retrieved from http://journal.nzma.org.nz/journal/123-1319/4230/content.pdf

Lewis, J. G., Borowski, K. K., Shand, B. I., George, P. M., & Scott, R. S. (2010). Plasma sex hormone-binding globulin, corticosteroid-binding globulin, cortisol, and free cortisol levels in outpatients attending a lipid disorders clinic: A cross-sectional study of 1137 subjects. Hormone & Metabolic Research, 42(4), 274-279. doi: 10.1055/s-0029-1243260

Simes, J., Voysey, M., O'Connell, R., Glasziou, P., Best, J. D., Scott, R., … for the FIELD Study Investigators, including Manning, P. (2010). A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials. PLoS ONE, 5(1), e8580. doi: 10.1371/journal.pone.0008580

Monro, J. A., Wallace, A., Mishra, S., Eady, S., Willis, J. A., Scott, R. S., & Hedderley, D. (2010). Relative glycaemic impact of customarily consumed portions of eighty-three foods measured by digesting in vitro and adjusting for food mass and apparent glucose disposal. British Journal of Nutrition, 104(3), 407-417. doi: 10.1017/S0007114510000589

Wallace, A., Eady, S., Miles, M., Martin, H., McLachlan, A., Rodier, M., Willis, J., Scott, R., & Sutherland, J. (2010). Demonstrating the safety of manuka honey UMF^® 20+ in a human clinical trial with healthy individuals. British Journal of Nutrition, 103(7), 1023-1028. doi: 10.1017/S0007114509992777

2009

Journal - Research Article

Shand, B. I., Scott, R. S., Lewis, J. G., Elder, P. A., & Frampton, C. M. (2009). Comparison of indices of insulin resistance with metabolic syndrome classifications to predict the development of impaired fasting glucose in overweight and obese subjects: A 3-year prospective study. International Journal of Obesity, 33(11), 1274-1279. doi: 10.1038/ijo.2009.169

Lewis, J. G., Shand, B. I., Frampton, C. M., Elder, P. A., & Scott, R. S. (2009). Plasma levels of sex hormone-binding globulin, corticosteroid-binding globulin and cortisol in overweight subjects who develop impaired fasting glucose: A 3-year prospective study. Hormone & Metabolic Research, 41(3), 255-259. doi: 10.1055/s-0028-1087190

Scott, R., O'Brien, R., Fulcher, G., Pardy, C., D'Emden, M., Tse, D., … on behalf of the Fenofibrate Intervention and Event Lowering in Diabete (FIELD) Study Investigators, including Manning, P. (2009). Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care, 32(3), 493-498. doi: 10.2337/dc08-1543

Lever, M., George, P. M., Slow, S., Elmslie, J. L., Scott, R. S., Richards, A. M., Fink, J. N., & Chambers, S. T. (2009). Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovascular Drugs & Therapy, 23(5), 395-401. doi: 10.1007/s10557-009-6188-1

Wallace, A. J., Eady, S. L., Willis, J. A., Scott, R. S., Monro, J. A., & Frampton, C. M. (2009). Variability in measurements of blood glucose response to foods in human subjects is not reduced after a standard breakfast. Nutrition Research, 29(4), 238-243. doi: 10.1016/j.nutres.2009.03.003

Miller, L. J., Pearce, J., Barnett, R., Willis, J., Darlow, B. A., & Scott, R. S. (2009). Is population mixing associated with childhood type 1 diabetes in Canterbury, New Zealand? Social Science & Medicine, 68(4), 625-630. doi: 10.1016/j.socscimed.2008.11.027

Elmslie, J. L., Porter, R. J., Joyce, P. R., Hunt, P. J., Shand, B. I., & Scott, R. S. (2009). Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Australian & New Zealand Journal of Psychiatry, 43(1), 53-60. doi: 10.1080/00048670802534341

Conference Contribution - Poster Presentation (not in published proceedings)

Sorrenson, B., Jones, G. T., Williams, M. J., Bickley, V. M., Scott, R. S., George, P. M., & McCormick, S. P. A. (2009, September). Functional studies of novel ABCA1 mutations associated with low HDL-cholesterol levels. Poster session presented at the Third Annual Division of Health Sciences Research Forum, Wellington, New Zealand.

Shand, B., Scott, R., Lewis, J., Elder, P., & Frampton, C. (2009, July). Comparison of commonly used markers of insulin resistance to predict the development of impaired fasting glucose in overweight subjects. Poster session presented at the 33rd New Zealand Society for the Study of Diabetes Annual Scientific Meeting, Dunedin, New Zealand.

Shand, B., Scott, R., & George, P. (2009, July). Comparison of clinical and biochemical parameters in subjects with and without diabetes attending a lipid disorders outpatient clinic. Poster session presented at the 33rd New Zealand Society for the Study of Diabetes Annual Scientific Meeting, Dunedin, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Shand, B., Florkowski, C., Scott, R., van der Hulst, S., & Reinisch, L. (2009, July). Assessment of a new non-invasive skin test to discriminate between people with and without diabetes. Verbal presentation at the 33rd New Zealand Society for the Study of Diabetes Annual Scientific Meeting, Dunedin, New Zealand.

Willis, J. A., Scott, R. S., & Darlow, B. A. (2009, July). Four decades of type 1 diabetes in Canterbury children and adolescents. Verbal presentation at the 33rd New Zealand Society for the Study of Diabetes Annual Scientific Meeting, Dunedin, New Zealand.

Film/Video/CD Rom

Fraser, R., Beaven, D., Scott, R., Willis, J., Shaw, G., & Chase, G. (2009). The Body, the Research, the Professor: Diabetes [Episode 2] [Film]. Christchurch, New Zealand: Canterbury Medical Research Foundation. Retrieved from http://www.cmrf.org.nz/Home/Videos/#vid1

2008

Journal - Research Article

Plant, S., Shand, B., Elder, P., & Scott, R. (2008). Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diabetes & Vascular Disease Research, 5(2), 102-108.

Homer, V. M., Marais, A. D., Charlton, F., Laurie, A. D., Hurndell, N., Scott, R., … George, P. M., & Lambert, G. (2008). Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 196(2), 659-666.

Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & Sitagliptin Study 801 Group. (2008). Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, Obesity & Metabolism, 10(10), 959-969.

Lewis, J. G., Shand, B. I., Elder, P. A., & Scott, R. S. (2008). Plasma retinol-binding protein is unlikely to be a useful marker of insulin resistance. Diabetes Research & Clinical Practice, 80(1), e13-e15.

Lewis, J. G., Shand, B. I., Frampton, C. M., Elder, P. A., & Scott, R. S. (2008). Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: A three year longitudinal study. Clinical Biochemistry, 41(13), 1034-1038.

Wallace, A. J., Eady, S. L., Scott, R. S., Willis, J. A., & Frampton, C. M. (2008). Considerable temporal variability in glucose reference curves in humans for a year period. Nutrition Research, 28(8), 495-500.

Chan, J. C., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., … Williams-Herman, D. (2008). Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity & Metabolism, 10(7), 545-555.

Young, J. M., Strey, C. H., George, P. M., Sies, C. W., Florkowski, C. M., Frampton, C. M., & Scott, R. S. (2008). Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. European Journal of Heart Failure, 10(5), 463-466. doi: 10.1016/j.ejheart.2008.03.010

Dawson, S. I., Willis, J., Florkowski, C. M., & Scott, R. S. (2008). All-cause mortality in insulin-treated diabetic patients: A 20-year follow-up. Diabetes Research & Clinical Practice, 80(1), e6-e9.

Dawson, S. I., Willis, J., Florkowski, C. M., & Scott, R. S. (2008). Cause-specific mortality in insulin-treated diabetic patients: A 20-year follow-up. Diabetes Research & Clinical Practice, 80(1), 16-23.

Conference Contribution - Published proceedings: Abstract

Shand, B., Scott, R., Elder, P., Lewis, J., & Frampton, C. (2008). Comparison of metabolic syndrome markers to predict changes in fasting glucose concentration in overweight, non-diabetic subjects. Diabetes Research and Clinical Practice. 79(Suppl. 1), (pp. S16). [Abstract]

Miller, L. J., Pearce, J., Willis, J. A., Barnett, R., Darlow, B. A., & Scott, R. S. (2008). Population mixing and type 1 diabetes in Canterbury. New Zealand Medical Journal, 121(1271). Retrieved from http://journal.nzma.org.nz/journal/121-1271/2990/content.pdf

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., George, P. M., & Scott, R. S. (2008). Is there a role for coenzyme Q10 supplementation in statin-induced myopathy? New Zealand Medical Journal, 121(1271). Retrieved from http://journal.nzma.org.nz/journal/121-1271/2990/content.pdf

Miller, L. J., Pearce, J., Willis, J. A., Barnett, R., Scott, R. S., & Darlow, B. A. (2008). Population mixing and Type 1 diabetes in Canterbury, New Zealand. Diabetes Research and Clinical Practice. 79(Suppl. 1), (pp. S36-S37). [Abstract]

Willis, J. A., Miller, L. J., Scott, R. S., Darlow, B. A., Pearce, J., & Barnett, R. (2008). Increasing incidence of Type 1 diabetes in Canterbury children and adolescents and spatial-temporal clustering. Diabetes Research and Clinical Practice. 79(Suppl. 1), (pp. S36). [Abstract]

Conference Contribution - Poster Presentation (not in published proceedings)

Sorrenson, B., Homer, V. M., Scott, R. S., George, P. M., & McCormick, S. P. A. (2008, November-December). Two different ABCA1 mutations in a family with familial hypoalphalipoproteinemia. Poster session presented at the New Zealand Institute of Chemistry, New Zealand Society for Biochemistry and Molecular Biology and the New Zealand Society of Plant Biologists Combined Conference, Dunedin, New Zealand.

2007

Journal - Research Article

Shand, B., Scott, R., Connolly, S., Clarke, R., Baker, J., Elder, P., Frampton, C., & Yeo, J. (2007). Comparative study on the efficacy of pioglitazone in Caucasian and Maori-Polynesian patients with poorly controlled type 2 diabetes. Diabetes, Obesity & Metabolism, 9, 540-547.

Shand, B., Elder, P., Scott, R., Poa, N., & Frampton, C. M. (2007). Comparison of plasma adiponectin levels in New Zealand Māori and Caucasian individuals. New Zealand Medical Journal, 120(1257). Retrieved from http://journal.nzma.org.nz/journal/120-1257/2606/content.pdf

Scott, R., Wu, M., Sanchez, M., & Stein, P. (2007). Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. International Journal of Clinical Practice, 61(1), 171-180.

Journal - Research Other

Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., George, P. M., & Scott, R. S. (2007). Effect of coenzyme Q₁₀ supplementation on simvastatin-induced myalgia. American Journal of Cardiology, 100, 1400-1403. doi: 10.1016/j.amjcard.2007.06.030

2006

Journal - Research Article

Wallace, A. J., Willis, J. A., Monro, J. A., Frampton, C. M., Hedderley, D. I., & Scott, R. S. (2006). No difference between venous and capillary blood sampling and the Minimed continuous glucose monitoring system for determining the blood glucose response to food. Nutrition Research, 26, 403-408.

Keech, A., Simes, J., Barter, P., Best, J., Scott, R., Taskinen, M.-R., & on behalf of the FIELD Management Committee. (2006). Correction to the FIELD study report. Lancet, 368, 1415. doi: 10.1016/S0140-6736(06)69594-9

Shand, B., Elder, P., Scott, R., Frampton, C., & Willis, J. (2006). Biovariability of plasma adiponectin. Clinical Chemistry & Laboratory Medicine, 44(10), 1164-1168.

Young, J. M., Shand, B. I., McGregor, P. M., Scott, R. S., & Frampton, C. M. (2006). Comparative effects of enzogenol((R)) and vitamin C supplementation versus vitamin C alone on endothelial function and biochemical markers of oxidative stress and inflammation in chronic smokers. Free Radical Research, 40(1), 85-94.

Wallace, A. J., Monro, J. A., Hedderley, D. I., Willis, J. A., & Scott, R. S. (2006). Determining the glycemic glucose equivalent value of foods in humans. Nutrition Research, 26, 47-52.

Strey, C. H., Young, J. M., Lainchbury, J. G., Frampton, C. M., Nicholls, M. G., Richards, A. M., & Scott, R. S. (2006). Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart, 92(11), 1603-1609. doi: 10.1136/hrt.2005.082560

The DIAMOND Project Group, including Darlow, B., Scott, R., & Willis, J. (2006). Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabetic Medicine, 23, 857-866.

Journal - Research Other

Willis, J., Raizis, A., Darlow, B., Scott, R., & Beaven, D. (2006). Type 1 diabetes: Research hopes and their New Zealand implications [Letter]. New Zealand Medical Journal, 119(1228). Retrieved from http://journal.nzma.org.nz/journal/119-1228/1819/content.pdf

Conference Contribution - Published proceedings: Abstract

Willis, J. A., Scott, R. S., Darlow, B. A., Nesbit, J. W., McRae, J. F., Johnstone, A. C., & Frampton, C. M. (2006). HLA-DQ alleles in children and adolescents with type 1 diabetes: Temporal changes. Proceedings of the New Zealand Society for the Study of Diabetes 30th Annual Scientific Meeting. (pp. 41). New Zealand Society for the Study of Diabetes. Retrieved from http://www.nzssd.org.nz/documents/NZSSD%20Handbook%202006.pdf

2005

Journal - Research Article

Scott, R., Best, J., Forder, P., Taskinen, M.-R., Simes, J., Barter, P., & Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate. Cardiovascular Diabetology, 4(13). Retrieved from http://www.cardiab.com/content/pdf/1475-2840-4-13.pdf

FIELD Study Investigators, including Scott, R., & Mann, S. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet, 366(9500), 1849-1861.

Lever, M., George, P. M., Dellow, W. J., Scott, R. S., & Chambers, S. T. (2005). Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. Metabolism, 54, 1-14.

Chee, L., Spearing, R. L., Morris, C. M., McDonald, M., Hanrahan, V., Ebbett, A., Scott, R., Florkowski, C., … Patton, W. N. (2005). Acquired myeloma-associated Type III hyperlipidaemia treated by nonmyeloablative HLA-identical sibling allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET): Evidence of engraftment without manifestation of ET in recipient. Bone Marrow Transplantation, 35, 1213-1214.

Strey, C. H., Young, J. M., Molyneux, S. L., George, P. M., Florkowski, C. M., Scott, R. S., & Frampton, C. M. (2005). Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis, 179(1), 201-206.

Journal - Research Other

Willis, J. A., Scott, R. S., & Darlow, B. A. (2005). -to: Campbell-Stokes PL, Taylor BJ on behalf of the New Zealand Children's Diabetes Working Group (2005) Prospective incidence study of diabetes mellitus in New Zealand children aged 0 to 14 years. Diabetologia 48: 643-648. Diabetologia, 48(11), 2442-2443.

Conference Contribution - Verbal presentation and other Conference outputs

Dawson, S. I., Florkowski, C. M., Willis, J. A., & Scott, R. S. (2005, May). Cause-specific and total mortality in the Canterbury insulin-treated diabetic registry population: A 20-year follow-up study. Verbal presentation at the New Zealand Society for the Study of Diabetes 29th Annual Scientific Meeting, Rotorua, New Zealand.

2004

Journal - Research Article

Lewis, J. G., Shand, B. I., Elder, P. A., & Scott, R. S. (2004). Plasma sex hormone-binding globulin rather than corticosteroid-binding globulin is a marker of insulin resistance in obese adult males. Diabetes, Obesity & Metabolism, 6(4), 259-263.

Strey, C. H., Young, J., Collier, M., Florkowski, C. M., Shand, B. I., & Scott, R. S. (2004). The postprandial state does not impair endothelial function in women with type 2 diabetes irrespective of glycaemic control. Diabetologia, 47(10), 1838-1846.

Laurie, A. D., Scott, R. S., & George, P. M. (2004). Genetic screening of patients with familial hypercholesterolaemia (FH): A New Zealand perspective. Atherosclerosis Supplements, 5(5), 13-15.

Lunt, H., Kendall, D., Moore, M. P., Scott, R. S., Cole, D., Frampton, C. M., & Cullens, M. (2004). Prospective audit of conversion from regular to lispro insulin during routine clinical care. Internal Medicine Journal, 34(3), 320-323.

Conference Contribution - Published proceedings: Abstract

Darlow, B. A., Willis, J. A., Scott, R. S., & Florkowski, C. M. (2004). Type 1 diabetes in New Zealand children and adolescents: Incidence, prevalence and mortality. Pediatric Research. 56(3), (pp. 474). [Abstract]

2003

Journal - Research Article

Florkowski, C. M., Scott, R. S., Graham, P. J., Han, D. Y., & Moir, C. L. (2003). Cause-specific and total mortality in the Canterbury (New Zealand) insulin-treated Diabetic Registry population: a 15-year follow-up study. Diabetic Medicine, 20(3), 191-197.

Shand, B., Strey, C. H., Scott, R. S., Morrison, Z., & Gieseg, S. P. (2003). Pilot study on the clinical effects of dietary supplementation with Enzogenol®, a flavonoid extract of pine bark and vitamin C. Phytotherapy Research, 17(5), 490-494. doi: 10.1002/ptr.1181

Phillips, P., Karrasch, J., Scott, R. S., Wilson, D., & Moses, R. (2003). Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. Diabetes Care, 26(2), 269-273.

Davidson, M. H., Ose, L., Frohlich, J., Scott, R. S., Dujovne, C. A., Escobar, I., … Mercuri, M. (2003). Differential effects of simvastation and atorvastation on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clinical Cardiology, 26(11), 509-514.

Hall, R. J., Merriman, M. E., Green, R. A., Markham, V. H., Smyth, D. J., Heward, J. M., … Braithwaite, A., … Darlow, B. A., … Harrison, A. A., Highton, J., Hunt, P. J., Manning, P. J., … Scott, R. S., Taylor, B. J., Willis, J., … Merriman, T. R. (2003). The Deleted in Colorectal Carcinoma (DCC) gene 201 R → G polymorphism: No evidence for genetic association with autoimmune disease. European Journal of Human Genetics, 11, 840-844.

Shand, B. I., Scott, R. S., Elder, P. A., & George, P. M. (2003). Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes, Obesity & Metabolism, 5(5), 349-353.

Journal - Professional & Other Non-Research Articles

Begg, E., Sidwell, A., Gardiner, S., Nicholls, G., & Scott, R. (2003). The sorry saga of the statins in New Zealand: Pharmacopolitics versus patient care [Viewpoint]. New Zealand Medical Journal, 116(1170). Retrieved from http://journal.nzma.org.nz/journal/116-1170/360/content.pdf

Ellis, C. J., & Scott, R. S. (2003). Statins and coenzyme Q10. Lancet, 361(9363), 1134-1135.

Conference Contribution - Published proceedings: Abstract

Willis, J., Scott, R. S., Florkowski, C. M., & Darlow, B. A. (2003). Type I diabetes in New Zealand children and adolescents: Incidence, prevalence and mortality. Diabetes & Metabolism. 29, (pp. 5S13). [Abstract]

2002

Journal - Research Article

de Jongh, S., Ose, L., Szamosi, T., Gagné, C., Lambert, M., Scott, R. S., … Kastelein, J. J. P. (2002). For the Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with Familial Hypercholesterolaemia. Circulation, 106, 2231-2237.

Scott, R. S. (2002). Stroke and heart disease prevention through lipid management. Hong Kong Practitioner, 24, 1-4.

Willis, J., Scott, R. S., Darlow, B. A., Lewy, H., Ashkenazi, I., & Laron, Z. (2002). Seasonality of birth and onset of clinical disease in children and adolescents (0 - 19 years) with Type 1 Diabetes Mellitus in Canterbury, New Zealand. Journal of Pediatric Endocrinology & Metabolism, 15(5), 645-647.

Bunn, C., Lintott, C. J., Scott, R. S., & George, P. M. (2002). Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Human Mutation, 19(3), 311.

Willis, J., Scott, R. S., Darlow, B. A., Nesbit, J., Anderson, P., Moore, M. P., Lunt, H., & Cole, D. R. (2002). Incidence of type 1 diabetes mellitus diagnosed before age 20 years in Canterbury, New Zealand over the last 30 years. Journal of Pediatric Endocrinology & Metabolism, 15, 637-643.

Journal - Professional & Other Non-Research Articles

Lunt, H., Kendall, D., Moore, M. P., Owens, N., Cole, D. R., Willis, J. A., Scott, R. S., & Darlow, B. A. (2002). Type 1 diabetes: glycaemic control during adolescence. New Zealand Medical Journal, 115(1167), U282. Retrieved from http://www.nzma.org.nz/journal/115-1167/282

Beard, M. E., Willis, J., Scott, R. S., & Nesbit, J. (2002). Is Type 1 Diabetes transmissible by a bone marrow allograft? Diabetes Care, 25(4), 799-800. Indianapolis: Diabetes Care.

Conference Contribution - Published proceedings: Abstract

Willis, J., Scott, R. S., Darlow, B. A., & Nesbit, J. (2002). Immunogenetic features of type 1 diabetes in children and adolescents: Temporal changes. Diabetes/ Metabolism Research and Reviews. 18(Suppl 4), (pp. S5). [Abstract]

Lunt, H., Kendall, D., Moore, M. P., & Scott, R. S. (2002). A prospective audit of conversion from soluble to Lispro insulin. Diabetes. 51(supplement), (pp. A473). United States: American Diabetes Association. [Abstract]

2001

Journal - Research Article

Brown, L. J., Scott, R. S., & Moir, C. L. (2001). All-cause mortality in the Canterbury (New Zealand) insulin-treated diabetic registry population. Diabetes Care, 24, 56-63.

Crossen, K., Scott, R. S., McGeoch, G. R. B., & George, P. M. (2001). Implementation of evidence based cardiovascular risk treatments by general practitioners. New Zealand Medical Journal, 114, 260-262.

Shand, B. I., Scott, R. S., Florkowski, C. M., Reynolds, M., & Ikram, H. (2001). A comparison of post-prandial changes in flow-mediated dilatation in patients with type 2 diabetes with and without macroalbuminuria. Diabetes Nutrition & Metabolism, 14, 201-206.

Collier, M., Shand, B. I., Scott, R. S., & Walmsley, T. A. (2001). The effect of magnesium supplementation on cardiovascular risk factors in people with type 2 diabetes. Journal New Zealand Dietetic Association, 55, 52-57.

Florkowski, C. M., Scott, R. S., Coope, P. A., & Moir, C. L. (2001). Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study. Diabetes Research & Clinical Practice, 52, 113-120.

Florkowski, C. M., Scott, R. S., Coope, P. A., Graham, P. J., & Moir, C. L. (2001). Age at diagnosis, glycaemic control and the development of retinopathy in a population-based cohort of type 1 diabetic subjects in Canterbury, New Zealand. Diabetes Research & Clinical Practice, 52, 125-131.

Conference Contribution - Published proceedings: Abstract

Willis, J. A., Scott, R. S., Darlow, B. A., Nesbit, J. W., Anderson, P., Moore, M. P., Lunt, H., & Cole, D. R. (2001). Gender and type 1 dianetes in New Zealand children and adolescents. Diabetologia, 44(Suppl. 1), (pp. A97). [Abstract]

Merriman, T., Hall, R., Merriman, M., Cundy, T., Darlow, B., Highton, J., … Mann, J., Manning, P., … Markham, V., Rossaak, J., Scott, R., Taylor, B., & Willis, J. (2001). Deleted in colorectal carcinoma (DCC): A candidate autoimmune susceptibility gene on chromosome 18. Internal Medicine Journal, 31(4), (pp. A5). doi: 10.1046/j.1445-5994.2001.0060a.x

Lee, H. Y., Shand, B. I., Scott, R. S., & Frampton, C. M. (2001). A comparison of established risk factors and increased blood viscosity to predict cardiovascular outcomes in patients with type 2 diabetes. Internal Medicine Journal. 31(Supplement), (pp. A9). [Abstract]

Willis, J., Scott, R. S., Darlow, B. A., Nesbit, J., Anderson, P., Moore, M. P., Lunt, H., & Cole, D. M. (2001). Gender and type 1 diabetes in Canterbury children and adolescents. Internal Medicine Journal. 31(Supplement), (pp. A7). [Abstract]

Willis, J. A., Scott, R. S., Darlow, B. A., Nesbit, J. W., Anderson, P., Moore, M. P., Lunt, H., & Cole, D. M. (2001). The incidence of Type 1 diabetes diagnosed before age 20 in Canterbury over the last 30 years. Internal Medicine Journal. 31(Supplement), (pp. A3). [Abstract]

2000

Journal - Research Article

Ose, L., Davidson, M. H., Stein, E. A., Kastelein, J. J. P., Scott, R. S., Junninghake, D., … Mitchel, Y. B. (2000). Lipid altering efficacy and safety of simvastatin 80 mg/day: Longterm experience in a large group of patients with hypercholesterolaemia. Clinical Cardiology, 23, 39-46.

Thiart, R., Varret, M., Lintott, C. J., Scott, R. S., Loubser, O., du Plessis, L., … Kotze, M. J. (2000). Mutation analysis in a small cohort of New Zealand patients originating from the United Kingdom demonstrates genetic heterogeneity in familial hypercholesterolaemia. Molecular & Cellular Probes, 14, 299-304.

Conference Contribution - Published proceedings: Abstract

Willis, J. A., Scott, R. S., Darlow, B. A., Nesbit, J. W., Moore, M. P., & Lunt, H. (2000). Type 1 diabetes diagnosed before age 20 in Canterbury. New Zealand Diabetes. 49(Suppl. 1), (pp. A179). [Abstract]

Willis, J., Scott, R. S., Darlow, B. A., Nesbit, J., Moore, P., & Lunt, H. (2000). Type 1 diabetes diagnosed before age 20 in Canterbury, New Zealand: 1970-1999. Diabetes. 49(Supplement 1), (pp. A179). [Abstract]

1999

Journal - Research Article

Nesbit, J. W., Willis, J. A., Scott, R. S., & Darlow, B. A. (1999). Susceptibility alleles for type 1 diabetes in childhood and adolescent diabetes cases and insulin deficient adult-onset diabetic subjects. Australian & New Zealand Journal of Medicine, 29, 597.

Florkowski, C. M., George, P. M., Willis, J., Stott, M. K., Burt, M. J., Upton, J. D., … Scott, R. S. (1999). Haemochromatosis gene mutations Cys282Tyr and His63Asp are not increased in type 2 diabetic patients compared with the Canterbury (New Zealand) general population. Diabetes Research & Clinical Practice, 43, 199-203.

Florkowski, C. M., & Scott, R. S. (1999). Type 2 diabetes towards the new millenium - the relative importance of glycaemic versus lipid control. Australian & New Zealand Journal of Medicine, 29, 249.

1998

Journal - Research Article

Mann, J., & Scott, R. S. (1998). Lipid-modifying drugs. New Zealand Medical Journal, 111, 285-287.

Florkowski, C. M., Scott, R. S., Moir, C. L., & Graham, P. J. (1998). Lipid but not glycaemic parameters predict total mortality from type 2 diabetes mellitus in Canterbury, New Zealand. Diabetic Medicine, 15(5), 386-392.

Florkowski, C. M., Scott, R. S., Moir, C. L., & Graham, P. J. (1998). Clinical and biochemical outcomes of type 2 diabetes mellitus in Canterbury, New Zealand: a 6-year cohort study. Diabetes Research & Clinical Practice, 40(3), 167-173.

Florkowski, C. M., & Scott, R. S. (1998). Outcomes of type 2 diabetes. Diabetes Reviews International, 7, 6-8.

Willis, J. A., Scott, R. S., Brown, L., Zimmet, P., MacKay, I., & Rowley, M. (1998). Type 1 diabetes in insulin-treated adult-onset diabetic subjects. Diabetes Research & Clinical Practice, 42, 49-53.

Payne, C., & Scott, R. S. (1998). Hospital discharges for diabetic foot disease in New Zealand: 1980 - 1993. Diabetes Research & Clinical Practice, 39, 69-74.

Simons, L. A., & Scott, R. S. (1998). Comparison of Atorvaststin alone versus Simvastatin + cholestyramine in the management of severe primary hypercholesterolaemia (The Six Cities Study). Australian & New Zealand Journal of Medicine, 28, 327-332.

Ose, L., Kastelein, J. J. P., Scott, R. S., Stein, E. A., Campodonico, S., Escobar, J. D., … Mercuri, M. (1998). Efficacy and six-month safety of simvastatin 80mg/day: Results from the Worldwide Simvastin Expanded Dose Program (WSEDP). Nutrition, Metabolism & Cardiovascular Diseases, 8, 143-151.

Conference Contribution - Published proceedings: Full paper

Willis, J., Scott, R. S., & Darlow, B. A. (1998). Sensitivity anti-GAD and anti-IA-2 measured by ELISA and ICA, for type 1 diabetes in newly-diagnosed children and adolescents. American Diabetes Association 58th Annual Meeting, Chicago, June 1998. [Full Paper]

Conference Contribution - Published proceedings: Abstract

Willis, J., Scott, R. S., & Darlow, B. A. (1998). Sensitivity anti-GAD and anti-IA-2 measured by ELISA and ICA for type 1 diabetes in children and adolescents. Diabetes. 47(Suppl. 1), (pp. A205). [Abstract]

1997

Journal - Research Article

Willis, J., Scott, R. S., Darlow, B. A., Lunt, H., & Moore, P. (1997). Hepatitis B immunisation and the epidemiology of IDDM in children and adolescents aged <20 years in Canterbury, New Zealand. Diabetes, 46(Suppl. 1), 140A.

Florkowski, C. M., Scott, R. S., Hart, J. B., Willis, J. A., & Campbell, A. (1997). The effect of gliclazide on insulin and proinsulin responses to mixed meal testing in non-insulin dependent diabetes subjects. Nutrition, Metabolism & Cardiovascular Diseases, 7(4), 331-335.

Journal - Professional & Other Non-Research Articles

Agarwal, M., Lunt, H., & Scott, R. S. (1997). Hormone Replacement therapy, diabetes and pancreatitus secondary to hyperglyceridaemia. New Zealand Medical Journal, 110, 426.

1996

Journal - Research Article

Willis, J. A., Scott, R. S., Brown, L. J., Forbes, L. V., Schmidli, R. S., Zimmet, P. Z., … Rowley, M. J. (1996). Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Research & Clinical Practice, 33(2), 89-97. doi: 10.1016/0168-8227(96)01281-8

1995

Journal - Research Article

Forbes, L. V., Scott, R. S., Brown, L. J., & Darlow, B. A. (1995). Immunogenetic, clinical and demographic characterization of childhood type 1 diabetes in New Zealand. Diabetes Care, 18(11), 1428-1433.

1993

Journal - Research Article

Schmidli, R. S., Hagan, C., Scott, R. S., Livesey, J., & Forbes, L. V. (1993). Plasma proinsulin in recently diagnosed type 2 diabetes mellitus. Diabetes Research & Clinical Practice, 20(2), 133-138. doi: 10.1016/0168-8227(93)90007-R

1992

Journal - Research Article

Scott, R. S., Brown, L. J., Darlow, B. A., Forbes, L. V., & Moore, M. P. (1992). Temporal variation in incidence of IDDM in Canterbury, New Zealand. Diabetes Care, 15(7), 895-899. doi: 10.2337/diacare.15.7.895